Proteomic analysis of dorsal root ganglia in a mouse model of paclitaxel-induced neuropathic pain

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Paclitaxel is a chemotherapy drug widely used for the treatment of various cancers based on its ability to potently stabilize cellular microtubules and block division in cancer cells. Paclitaxel-based treatment, however, accumulates in peripheral system sensory neurons and leads to a high incidence rate (over 50%) of chemotherapy induced peripheral neuropathy in patients. Using an established preclinical model of paclitaxel-induced peripheral neuropathy (PIPN), we examined proteomic changes in dorsal root ganglia (DRG) of adult male mice that were treated with paclitaxel (8 mg/kg, at 4 injections every other day) relative to vehicle-treated mice. High throughput proteomics based on liquid chromatography electrospray ionization mass spectrometry identified 165 significantly altered proteins in lumbar DRG. Gene ontology enrichment and bioinformatic analysis revealed an effect of paclitaxel on pathways for mitochondrial regulation, axonal function, and inflammatory purinergic signaling as well as microtubule activity. These findings provide insight into molecular mechanisms that can contribute to PIPN in patients.

Cite

CITATION STYLE

APA

Hanna, R., Graur, A., Sinclair, P., McKiver, B. D., Bos, P. D., Damaj, M. I., & Kabbani, N. (2024). Proteomic analysis of dorsal root ganglia in a mouse model of paclitaxel-induced neuropathic pain. PLoS ONE, 19(9 September). https://doi.org/10.1371/journal.pone.0306498

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free